ExonHit's $32M Bid for RedPath Will Open Door to US Molecular Dx Market

The pending deal also aims open the European pathology market to Pittsburgh-based RedPath's molecular assay line, which is currently limited to pancreatic cancer.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.